Palisade Bio Inc (PALI)

Apr 13, 2026

Piper Sandler reiterates Overweight rating on Palisade Bio stock - Investing.com UK

Apr 13, 2026

Apr 13, 2026

Piper Sandler reiterates Overweight rating on Palisade Bio stock By Investing.com - Investing.com India

Apr 13, 2026

Apr 12, 2026

Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher - MSN

Apr 12, 2026

Apr 11, 2026

Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Apr 11, 2026

Apr 10, 2026

Should I invest in Palisade Bio Inc before earnings2026 Performance Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn

Apr 10, 2026

Apr 10, 2026

Wolfe Research Upgrades Palisade Bio (NASDAQ:PALI) to Strong-Buy - MarketBeat

Apr 10, 2026

Apr 09, 2026

Wolfe Research Begins Coverage on Palisade Bio (NASDAQ:PALI) - MarketBeat

Apr 09, 2026

Apr 08, 2026

Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference - The Manila Times

Apr 08, 2026

Apr 08, 2026

Palisade Bio CEO, CMO to give virtual Needham presentation April 16 - Stock Titan

Apr 08, 2026

Apr 08, 2026

Palisade Bio (PALI) reports positive phase 1b data for PALI-2108 in UC patients - MSN

Apr 08, 2026

Apr 07, 2026

Earnings Miss: Can Palisade Bio Inc expand its profit margins2026 Opening Moves & Weekly High Return Opportunities - baoquankhu1.vn

Apr 07, 2026

Apr 05, 2026

Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail

Apr 05, 2026

Apr 03, 2026

PALI Should I Buy - Intellectia AI

Apr 03, 2026

Apr 02, 2026

Palisade Bio partners with Iterative Health to advance PALI-2108 - TipRanks

Apr 02, 2026

Apr 02, 2026

Palisade Bio enters agreement with Iterative Health and completes $3 million stock sale - Investing.com Australia

Apr 02, 2026

Apr 02, 2026

Palisade Bio raises $3.0M from Iterative Health affiliate to support PALI-2108 Phase 2 enrollment - TradingView — Track All Markets

Apr 02, 2026

Apr 02, 2026

Palisade Bio (NASDAQ: PALI) sells 1.54M shares to Iterative Health affiliate - Stock Titan

Apr 02, 2026

Apr 01, 2026

Palisade Bio, Inc. (PALI) stock price, news, quote and history - Yahoo Finance UK

Apr 01, 2026

Apr 01, 2026

Clear Street Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $12 - Moomoo

Apr 01, 2026

Apr 01, 2026

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Edwards Lifesciences (EW) and Palisade Bio (PALI) - The Globe and Mail

Apr 01, 2026

Mar 31, 2026

Clear Street reiterates Palisade Bio stock rating on trial data By Investing.com - Investing.com South Africa

Mar 31, 2026

Mar 31, 2026

Update: Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease - moomoo.com

Mar 31, 2026

Mar 31, 2026

Clear Street reiterates Palisade Bio stock rating on trial data - Investing.com

Mar 31, 2026

Mar 31, 2026

Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease - marketscreener.com

Mar 31, 2026

Mar 31, 2026

Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn’s Efficacy Signals - MarketBeat

Mar 31, 2026

Mar 31, 2026

Support Test: Can Palisade Bio Inc beat the S P 500Market Growth Summary & Weekly Momentum Picks - baoquankhu1.vn

Mar 31, 2026

Mar 31, 2026

Palisade Bio posts trial data for lead asset (PALI:NASDAQ) - Seeking Alpha

Mar 31, 2026

Mar 31, 2026

Crafting a New Financial Era: Palisade Bio Inc.’s Strategic Moves - StocksToTrade

Mar 31, 2026

Mar 31, 2026

Palisade Bio stock maintains buy rating at Stifel on trial data - Investing.com Australia

Mar 31, 2026

Mar 31, 2026

Palisade Bio stock maintains buy rating at Stifel on trial data By Investing.com - Investing.com South Africa

Mar 31, 2026

Mar 31, 2026

H.C. Wainwright Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7 - moomoo.com

Mar 31, 2026

Mar 31, 2026

Palisade Bio reports Phase 1b trial results for Crohn’s drug By Investing.com - Investing.com South Africa

Mar 31, 2026

Mar 30, 2026

Palisade Bio reports Phase 1b trial results for Crohn’s drug - Investing.com

Mar 30, 2026

Mar 30, 2026

Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease - GlobeNewswire

Mar 30, 2026

Mar 30, 2026

HC Wainwright Forecasts Palisade Bio Q1 Earnings - MarketBeat

Mar 30, 2026

Mar 27, 2026

Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Mar 27, 2026

Mar 26, 2026

HC Wainwright Begins Coverage on Palisade Bio (NASDAQ:PALI) - marketbeat.com

Mar 26, 2026

Mar 26, 2026

Palisade Bio, Inc. announced that it has received $3 million in funding from Iterative Scopes, Inc. - marketscreener.com

Mar 26, 2026

Mar 24, 2026

Big Picture: Can Palisade Bio Inc expand its profit marginsMarket Performance Summary & Free Accurate Trade Setup Notifications - baoquankhu1.vn

Mar 24, 2026

Mar 23, 2026

PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 23, 2026

Mar 23, 2026

Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating - Seeking Alpha

Mar 23, 2026

Mar 21, 2026

Palisade Bio 2026 10-K: Clinical Development, Risk Factors, and Precision Medicine Strategies for IBD - Minichart

Mar 21, 2026

Mar 21, 2026

Aug Spikes: Can Palisade Bio Inc expand its profit marginsQuarterly Earnings Report & Weekly Return Optimization Alerts - baoquankhu1.vn

Mar 21, 2026

Mar 20, 2026

Palisade Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 20, 2026

Mar 20, 2026

Palisade Bio (NASDAQ:PALI) Issues Quarterly Earnings Results, Beats Estimates By $1.10 EPS - MarketBeat

Mar 20, 2026

Mar 20, 2026

Palisade Bio Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView

Mar 20, 2026

Mar 20, 2026

Palisade Bio 10-K: Net loss $16.8M, EPS $(0.30) - TradingView

Mar 20, 2026

Mar 20, 2026

[10-K] PALISADE BIO, INC. Files An... - Stock Titan

Mar 20, 2026